PT-141 for Sale — Buyer Guide 2026
PT-141 (bremelanotide) is a melanocortin receptor agonist — the only FDA-approved peptide in this class (as Vyleesi) for a specific indication. In the research market, PT-141 is sold by peptide vendors. Before purchasing, verify COAs confirming ≥98% purity, research-use-only labeling, and be aware that research-market PT-141 is NOT the FDA-approved pharmaceutical product.
Midwest Peptide
10% off with code SQUARETABLE10 · 30-day cookie · 10% recurring commission
What PT-141 Is
PT-141, also known as bremelanotide, is a synthetic peptide that acts as an agonist at melanocortin receptors (MC3R and MC4R). It was developed from earlier research on melanotan peptides. In 2019, bremelanotide received FDA approval under the brand name Vyleesi for a specific indication. This is important for buyers: the research-market PT-141 sold by peptide vendors is NOT the same as the FDA-approved pharmaceutical. Research vendors sell the peptide as a chemical for laboratory study — not as an equivalent to Vyleesi or any approved product.5 Checks Before Buying
- Batch-linked third-party COA: Independent laboratory testing with HPLC chromatograms matching a specific batch/lot number. This is non-negotiable for any peptide vendor.
- Purity ≥98% with visible data: Demand HPLC chromatograms or MS spectra. PT-141's commercial relevance makes it attractive to counterfeiters — analytical data matters more than stated percentages.
- Clear research framing, no equivalence claims: Vendors that claim their PT-141 is 'the same as Vyleysi' or 'equivalent to FDA-approved' products are making false statements and should be avoided immediately.
- Transparent pricing and documentation: Legitimate vendors provide clear pricing, batch documentation, and policies. Vague listings with no documentation transparency carry higher risk.
- Documentation currency: COAs and testing reports within 6-12 months for active inventory.
Vendor Evaluation Table
| Vendor | COA / Testing Signal | Transparency Score | Risk Level |
|---|---|---|---|
| Peptide Partners | Four-lab roster + contaminant-panel archive | 78/100 · S tier | Low |
| OROS Research | ISO 17025 lab + per-lot testing posture | 75/100 · S tier | Low |
| Pure Peptides | Product-level MZ Biolabs COAs | 73/100 · A tier | Low |
| Crush Research | Four named labs + multi-vial methodology claim | 70/100 · A tier | Medium |
| Kimera Chems | Live COA archive + ISO 17025 lab partner signal | 70/100 · A tier | Medium |
| Elite Research USA | Per-product COAs + three named labs | 70/100 · A tier | Medium |
Seed evaluation from Matt's Reptides intake. Each claim should be re-verified against primary sources before final publication.
Red Flags That Mean Walk Away
Immediately avoid any PT-141 vendor that: claims equivalence to Vyleesi or any FDA-approved product, provides dosing guidance or administration protocols, markets with health-outcome language, sells through peer marketplaces or social media, cannot provide a batch-linked COA, or uses pricing that seems too good to be true. Because PT-141 has an approved pharmaceutical counterpart, vendors that blur the line between research chemical and pharmaceutical product are outside acceptable practices.Frequently Asked Questions
Is PT-141 the same as Vyleesi?
No. Vyleesi is the FDA-approved pharmaceutical formulation of bremelanotide (PT-141) manufactured under GMP standards for a specific approved indication. Research-market PT-141 is sold as a chemical for laboratory study only — it is not manufactured to pharmaceutical standards, has not undergone FDA review, and is not equivalent to Vyleesi in formulation, purity assurance, or regulatory status.
Has PT-141 been FDA-approved?
Bremelanotide (the active compound also referred to as PT-141) received FDA approval in 2019 under the brand name Vyleesi for a specific indication. This approval applies to the pharmaceutical product manufactured by the sponsoring company — not to research-market PT-141 sold by peptide vendors. Research versions have not been reviewed or approved by the FDA.
How do I verify a PT-141 COA?
A legitimate COA should come from an ISO-accredited independent laboratory, include batch/lot identification matching the product listing, show HPLC chromatograms or mass-spectrometry results, and be dated. Independently verify the laboratory exists through a web search. Given PT-141's pharmaceutical relevance, extra caution is warranted.
Are there counterfeit PT-141 products?
Yes. Because PT-141 has a known pharmaceutical counterpart and commercial relevance, it is a target for counterfeit products. Products sold through peer marketplaces, social media, or vendors without independently verifiable COAs may contain different compounds, incorrect dosages, or adulterants. Always research vendors before purchasing.
What is the difference between PT-141 and Melanotan II?
PT-141 (bremelanotide) and Melanotan II (MT-II) are related melanocortin agonists but they are different compounds. MT-II was never FDA-approved and has primarily been studied for tanning properties. PT-141/bremelanotide was developed from the same research family and received FDA approval as Vyleesi. They have different receptor affinity profiles and distinct research applications.
Related Pages
Peptide Vendor Rankings → · How to Read a COA → · Our Evaluation Methodology →
Verification Notes for PT-141 for Sale — Buyer Guide 2026
This file is reviewed as part of the The Peptide Reviewer documentation system, which means the page is not judged by headline confidence alone. The desk checks whether the claim has a date, whether the source can be opened by a reader, whether commercial language is separated from editorial scoring, and whether a medical or regulatory boundary is visible before the reader reaches any vendor context.
For pt 141 for sale, the practical standard is source literacy. A reader should be able to trace the page back to primary records, compare those records with the current vendor or compound claim, and see what the page does not prove. If a vendor changes a COA, removes a lab report, edits a product page, or adds health-outcome language after this review date, the conclusion can change. That is why this publication keeps source dates, correction rules, and reviewer scope close to the article body instead of hiding them in a footer.
The editorial team uses the same baseline checks across peptide vendor reviews, compound explainers, comparison pages, trust pages, and author pages. First, the page must identify the entity or topic clearly. Second, it must point readers toward primary-source verification. Third, it must avoid personal-use instructions and medical recommendations. Fourth, it must disclose when affiliate economics could exist and state that payment does not change scoring, inclusion, risk labels, or rank order.
When the page discusses a compound, the review separates published research context from research-market product claims. Published studies, trial records, or regulatory documents can describe a molecule, but they do not verify a private vendor batch. When the page discusses a vendor, the review separates a vendor's public marketing from documentation that can be checked, including batch-linked certificates, lab identity, source dates, claims language, and correction history.
Readers should treat this file as an audit trail, not a shortcut. The safest way to use it is to open the listed sources, confirm the current date on the vendor or regulatory record, and compare that source with the page summary. If the source and summary disagree, the source wins until the page is corrected. If the source cannot be found, the claim should be treated as unverified.
This added review note also gives crawlers and readers the same context that the editors use internally: what kind of evidence matters, which trust pages govern the file, who owns the review boundary, and where a correction should start. That matters most on author, policy, and directory pages because those pages can look thin even when they carry important E-E-A-T signals. The added context makes the page auditable without turning it into a new article.
- PubMed for published biomedical literature and review context.
- ClinicalTrials.gov for registered trial status and study records.
- FDA for approval status, warning letters, labeling, and regulatory context.
Frequently Asked Questions
How should I verify this page?
Start with the date, then open the primary source rather than relying on a summary. For medical or regulatory context, check PubMed, ClinicalTrials.gov, and FDA records. For vendor context, check the live vendor page, the batch-linked COA, the named lab, and any archived claim record.
Does this page provide medical advice?
No. The Peptide Reviewer publishes editorial source checks and market-transparency reviews. It does not provide treatment advice, dosing protocols, cycles, stacks, injection instructions, reconstitution guidance, diagnosis help, or personal-use recommendations.
Can affiliate relationships change the conclusion?
No. Affiliate relationships, sponsored links, and referral economics do not change scoring, inclusion, rank position, risk labels, author attribution, or medical-review status. Any paid link must be disclosed before the link and marked with sponsored nofollow attributes.
What happens if a source changes?
The page should be updated through the corrections process. A new COA, a changed vendor claim, an FDA update, or a corrected trial record can change the page. Until that update is made, readers should trust the current primary source over the older summary.
Related Standards
Methodology → · Editorial Standards → · Medical Review Policy → · Corrections Policy → · Affiliate Disclosure →